Significant Correction of Disease After Postnatal Administration of Recombinant Ectodysplasin A in Canine X-Linked Ectodermal Dysplasia

    October 2007 in “ American Journal of Human Genetics ”
    Margret L. Casal, John R. Lewis, Elizabeth A. Mauldin, Aubry Tardivel, Karine Ingold, Manuel Favre, Fabrice Paradies, Stéphane Demotz, Olivier Gaide, Pascal Schneider
    Image of study
    TLDR Giving a special protein to dogs with a certain genetic disease improved their symptoms but didn't help with hair growth.
    In the 2007 study, researchers found that postnatal administration of recombinant ectodysplasin A (Fc:EDA1) to dogs with X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) resulted in significant improvements in symptoms of the disease. The treatment was particularly effective in developing a more complete and anatomically correct adult dentition, improving mucociliary clearance, enhancing lacrimation to near wild-type levels, and enabling the ability to sweat. However, it did not affect hair growth. The study involved 9 dogs in total, with 3 receiving a single injection, 1 receiving four injections, and 5 receiving five higher doses under the T5x2 protocol. The findings suggest that such treatment could be beneficial for human patients with XLHED, although the timing of treatment is crucial due to differences in developmental stages between dogs and humans.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 8 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Tropoelastin injections + verteporfin?

      in Research/Science  13 upvotes 1 year ago
      The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

      community Androgen degraders for hair loss

      in Research/Science  62 upvotes 3 months ago
      The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

    Similar Research

    5 / 1000+ results